| Original language | English |
|---|---|
| Pages (from-to) | 177-182 |
| Number of pages | 6 |
| Journal | Sexually Transmitted Infections |
| Volume | 97 |
| Issue number | 3 |
| DOIs | |
| Publication status | Published (VoR) - 1 May 2021 |
Funding
Disclaimer This paper presents independent research funded by the National Institute for Health Research (NIHR) under its Research for Patient Benefit (RfPB) Programme (Grant Reference Number PB-PG-0609–19279). The views expressed are those of the author(s) and not necessarily those of the NIHR or the Department of Health and Social Care.
Keywords
- azithromycin
- mycoplasma
- pelvic inflammatory disease
Fingerprint
Dive into the research topics of 'Treatment of mild-to-moderate pelvic inflammatory disease with a short-course azithromycin-based regimen versus ofloxacin plus metronidazole: Results of a multicentre, randomised controlled trial'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver